The Cerebellum

, Volume 12, Issue 2, pp 176–193 | Cite as

Spinocerebellar Ataxia Type 7: Clinical Course, Phenotype–Genotype Correlations, and Neuropathology

  • Laura C. Horton
  • Matthew P. Frosch
  • Mark G. Vangel
  • Carol Weigel-DiFranco
  • Eliot L. Berson
  • Jeremy D. SchmahmannEmail author
Original Paper


Spinocerebellar ataxia type 7 is a neurodegenerative polyglutamine disease characterized by ataxia and retinal degeneration. The longitudinal course is unknown, and relationships between repeat expansion, clinical manifestations, and neuropathology remain uncertain. We followed 16 affected individuals of a 61-member kindred over 27 years with electroretinograms, neurological examinations including the Brief Ataxia Rating Scale, neuroimaging in five, and autopsy in four cases. We identified four stages of the illness: Stage 0, gene-positive but phenotypically silent; Stage 1, no symptoms, but hyperreflexia and/or abnormal electroretinograms; Stage 2, symptoms and signs progress modestly; and Stage 3, rapid clinical progression. CAG repeat length correlated inversely with age of onset of visual or motor signs (r = −0.74, p = 0.002). Stage 3 rate of progression did not differ between cases (p = 0.18). Electroretinograms correlated with Brief Ataxia Rating Scale score and were a biomarker of disease onset and progression. All symptomatic patients developed gait ataxia, extremity dysmetria, dysarthria, dysrhythmia, and oculomotor abnormalities. Funduscopy revealed pale optic discs and pigmentary disturbances. Visual acuity declined to blindness in those with longer CAG expansions. Hyperreflexia was present from Stage 1 onwards. Restless legs syndrome and sensory impairment were common. Neuropathological hallmarks were neuronal loss in cerebellar cortex, deep cerebellar nuclei, inferior olive, and anterior horns of the spinal cord, and axonal loss in spinocerebellar tracts, dorsal nerve roots, and posterior columns. Retinal pathology included photoreceptor degeneration and disruption of retinal pigment epithelium. Spinocerebellar ataxia type 7 evolves through four clinical stages; neuropathological findings underlie the clinical presentation; electroretinograms are a potential biomarker of disease progression.


Trinucleotide repeat expansion Cerebellum Ataxia Pathology Electroretinography 



Our paper is dedicated to the members of this family, whose personal resolve and commitment to this study are inspirational. Dr. Katherine B. Sims performed the original genetic testing in this family. The assistance of Jason MacMore is gratefully acknowledged.


This work was supported by the MINDlink Foundation, the Birmingham Foundation, the Foundation Fighting Blindness, and the Massachusetts Alzheimer Disease Research Center [AG05134].

Conflicts of interest



  1. 1.
    Enevoldson TP, Sanders MD, Harding AE. Autosomal dominant cerebellar ataxia with pigmentary macular dystrophy: a clinical and genetic study of eight families. Brain. 1994;117:445–60.PubMedCrossRefGoogle Scholar
  2. 2.
    David G, Durr A, Stevanin G, Cancel G, Abbas N, Benomar A, et al. Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy. Hum Mol Genet. 1998;7:165–70.PubMedCrossRefGoogle Scholar
  3. 3.
    Yamada M, Sato T, Tsuji S, Takahashi H. CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol. 2008;115:71–86.PubMedCrossRefGoogle Scholar
  4. 4.
    Helmlinger D, Hardy S, Sasorith S, Klein F, Robert F, Weber C, et al. Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum Mol Genet. 2004;13:1257–65.PubMedCrossRefGoogle Scholar
  5. 5.
    David G, Abbas N, Stevanin G, Durr A, Yvert G, Cancel G, et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet. 1997;17:65–70.PubMedCrossRefGoogle Scholar
  6. 6.
    Martin J, Van Regemorter N, Del-Favero J, Löfgren A, Van Broeckhoven C. Spinocerebellar ataxia type 7 (SCA7)—correlations between phenotype and genotype in one large Belgian family. J Neurol Sci. 1999;168:37–46.PubMedCrossRefGoogle Scholar
  7. 7.
    To KW, Adamian M, Jakobiec FA, Berson EL. Olivopontocerebellar atrophy with retinal degeneration. An electroretinographic and histopathologic investigation. Ophthalmology. 1993;100:15–23.PubMedGoogle Scholar
  8. 8.
    Schmahmann JD, Gardner R, MacMore J, Vangel MG. Development of a brief ataxia rating scale (BARS) based on a modified form of the ICARS. Mov Disord. 2009;24:1820–8.PubMedCrossRefGoogle Scholar
  9. 9.
    R Foundation for Statistical Computing [homepage on the Internet]. Vienna, Austria: Institute for Statistics and Mathematics; c1998-2011 [cited 2011 Mar 30]. R: A Language and Environment for Statistical Computing. Available from:
  10. 10.
    Bates DM, DebRoy S. Linear mixed models and penalized least squares. J Multivar Anal. 2004;91:1–17.CrossRefGoogle Scholar
  11. 11.
    Therneau TM, Grambsch PM. Modeling survival data: Extending the Cox model. New York: Springer; 2000.Google Scholar
  12. 12.
    Rabin AR, Berson EL. A full-field system for clinical electroretinography. Arch Ophthalmol. 1974;92:59–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel-DiFranco C, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993;111:761–72.PubMedCrossRefGoogle Scholar
  14. 14.
    Sandberg MA, Jacobson SG, Berson EL. Foveal cone electroretinograms in retinitis pigmentosa and juvenile macular degeneration. Am J Ophthalmol. 1979;88:702–7.PubMedGoogle Scholar
  15. 15.
    Johansson J, Forsgren L, Sandgren O, Brice A, Holmberg M. Extended CAG repeats in Swedish spinocerebellar ataxia type 7 (SCA7) patients: effect of CAG repeat length on the clinical manifestation. Hum Mol Genet. 1998;7:171–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Zar J. Biostatistical analysis. Englewood Cliffs: Prentice Hall; 1984.Google Scholar
  17. 17.
    Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology. 2011;77:1035–41.PubMedCrossRefGoogle Scholar
  18. 18.
    Ashizawa T, Perlman S, Gomez C, Wilmot G, Schmahmann J, Ying S, et al. Clinical characteristics of spinocerebellar ataxias 1, 2, 3, and 6. Abstract presented at: The American Academy of Neurology 65th Annual Meeting; 2012 April 24; New Orleans.Google Scholar
  19. 19.
    Holmberg M, Duyckaeerts C, Durr A, Cancel G, Gourfinkel-An I, Damier P, et al. Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet. 1998;7:913–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Koeppen AH. The pathogenesis of spinocerebellar ataxia. Cerebellum. 2005;4:62–73.PubMedCrossRefGoogle Scholar
  21. 21.
    Neetens A, Martin JJ, Libert J, Van den Ende P. Autosomal dominant cone dystrophy-cerebellar atrophy (ADCoCA) (modified ADCA Harding II). Neuro-ophthalmol. 1990;10:261–75.CrossRefGoogle Scholar
  22. 22.
    Ansorge O, Giunti P, Michalik A, Van Broeckhoven C, Harding B, Wood N, et al. Ataxin-7 aggregation and ubiquitination in infantile SCA7 with 180 CAG repeats. Ann Neurol. 2004;56:448–52.PubMedCrossRefGoogle Scholar
  23. 23.
    Middleton FA, Strick PL. Anatomical evidence for cerebellar and basal ganglia involvement in higher cognitive function. Science. 1994;266:458–61.PubMedCrossRefGoogle Scholar
  24. 24.
    Manrique RK, Noval S, Aguilar-Amat MJ, Arpa J, Rosa I, Contreras I. Ophthalmic features of spinocerebellar ataxia type 7. J Neuroophthalmol. 2009;29:174–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Miller RC, Tewari A, Miller JA, Garbern J, Van Stavern GP. Neuro-ophthalmologic features of spinocerebellar ataxia type 7. J Neuroophthalmol. 2009;29:180–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Oh AK, Jacobson KM, Jen JC, Baloh RW. Slowing of voluntary and involuntary saccades: an early sign in spinocerebellar ataxia type 7. Ann Neurol. 2001;49:801–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Martin J, Van Regemorter N, Krols L, Brucher JM, de Barsy T, Szliwowski H, et al. On an autosomal dominant form of retinal-cerebellar degeneration: an autopsy study of five patients in one family. Acta Neuropathol. 1994;88:277–86.PubMedCrossRefGoogle Scholar
  28. 28.
    Kedia S, Moro E, Tagliati M, Lang AE, Kumar R. Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. Neurology. 2004;63:2410–2.PubMedCrossRefGoogle Scholar
  29. 29.
    Driver-Dunckley E, Evidente VGH, Adler CH, Hillman R, Hernandez J, Fletcher G, et al. Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation. Mov Disord. 2006;21:1287–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Elden AC, Kim H, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expanions are associated with increased risk for ALS. Nature. 2010;466:1069–75.PubMedCrossRefGoogle Scholar
  31. 31.
    Holmes G. The cerebellum of man. Brain. 1939;62:1–30.CrossRefGoogle Scholar
  32. 32.
    Brown P. Pathophysiology of spasticity. J Neurol Neurosurg Psychiatry. 1994;57:773–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain. 1998;121:561–79.PubMedCrossRefGoogle Scholar
  34. 34.
    Berson EL. Long-term visual prognoses in patients with retinitis pigmentosa: the Ludwig von Sallmann lecture. Exp Eye Res. 2007;85:7–14.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Laura C. Horton
    • 1
  • Matthew P. Frosch
    • 2
  • Mark G. Vangel
    • 3
  • Carol Weigel-DiFranco
    • 4
  • Eliot L. Berson
    • 4
  • Jeremy D. Schmahmann
    • 1
    Email author
  1. 1.Ataxia Unit, Cognitive and Behavioral Neurology Unit, Laboratory for Neuroanatomy and Cerebellar Neurobiology, Department of NeurologyMassachusetts General Hospital and Harvard Medical SchoolBostonUSA
  2. 2.C.S. Kubik Laboratory for Neuropathology, Pathology ServiceMassachusetts General HospitalBostonUSA
  3. 3.Athinoula A. Martinos Center for Biomedical ImagingMassachusetts General HospitalBostonUSA
  4. 4.Berman-Gund Laboratory for the Study of Retinal Degenerations, Department of OphthalmologyHarvard Medical School, Massachusetts Eye and Ear InfirmaryBostonUSA

Personalised recommendations